A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies.

<h4>Background</h4>A major perspective for the use of circulating tumor DNA (ctDNA) in the clinical setting of non-small cell lung cancer (NSCLC) is expected as predictive factor for resistance and response to EGFR TKI therapy and, especially, as a non-invasive alternative to tissue biop...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Steffen Grann Jensen, Samantha Epistolio, Cesilie Lind Madsen, Majbritt Hauge Kyneb, Alice Riva, Alessia Paganotti, Jessica Barizzi, Rasmus Koefoed Petersen, Michael Børgesen, Francesca Molinari, Renzo Boldorini, Jan Lorenzen, Erik Sørensen, Ulf Bech Christensen, Estrid Høgdall, Milo Frattini
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/ff998aa9327d45aaa5565f0293d06c8b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!